Human B7-H6 Antibody

NKp30 Binding to B7-H6 Blocked by Human B7-H6 Antibody In a functional ELISA, 20-120 ng/mL of Mouse Anti-Human B7-H6 Monoclonal Antibody (Catalog # MAB71444) will block 50% of the binding of 20 ng/mL of Recombinant Human NKp30 Fc Chimera Protein (1849-NK) to immobilized Recombinant Human B7-H6 His-tag Protein (9309-B7) coated at 1 μg/mL (100 µL/well). At 1 μg/mL, this antibody will block >80% of the binding.

Detection of Human B7-H6 by Flow Cytometry B7H6 expression in human PC cell lines and generation of B7H6 KO PC cell lines. (A) Surface expression of B7H6 on human pancreatic cancer cell lines (PANC-1, CFPAC-1, Capan-1, PL45) was assessed with a Fortessa X20 flow cytometer. (B) Immunoblotting detected B7H6 protein expression in human pancreatic cancer cell lines, with K562 as a positive control. GAPDH was used as a loading control. (C) sB7H6 secreted by pancreatic cancer cells into supernatants at 24 and 48 hours was analyzed by ELISA. Medium collected from K562 or RPMI-1640 served as a positive or negative control, respectively. Data from at least 3 independent experiments are shown as mean ± SEM. (D) Immunoblotting detected the protein expression of B7H6 after what was knocked out by CRISPR/Cas9 from PANC-1 and Capan-1 cells. beta -actin was the internal control (E) Quantification of B7H6 protein expression on PANC-1 and Capan-1 cells normalized to beta -actin. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35311080), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human B7-H6 by Immunohistochemistry B7H6 expression in human pancreatic cancer tissues. (A) IHC staining of B7H6 in tumor (right) and adjacent tissues (left) of a pancreatic cancer patient’s specimens (magnification: Middle, 10×; right and left, 100×). (B) B7H6 expression in benign human organs shown by IHC staining of B7H6 (magnification: 100×). (C) Kaplan-Meier survival analysis of overall survival between PC patients who carried B7H6-positive or -negative tumors. P=0.017. (D) Kaplan-Meier analysis of overall survival between patients with high levels of B7H6 (H score ≥ 47) and those with low levels (H-score < 47). P<0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35311080), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human B7-H6 by Immunohistochemistry B7H6 expression in human pancreatic cancer tissues. (A) IHC staining of B7H6 in tumor (right) and adjacent tissues (left) of a pancreatic cancer patient’s specimens (magnification: Middle, 10×; right and left, 100×). (B) B7H6 expression in benign human organs shown by IHC staining of B7H6 (magnification: 100×). (C) Kaplan-Meier survival analysis of overall survival between PC patients who carried B7H6-positive or -negative tumors. P=0.017. (D) Kaplan-Meier analysis of overall survival between patients with high levels of B7H6 (H score ≥ 47) and those with low levels (H-score < 47). P<0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35311080), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human B7-H6 by Western Blot B7H6 expression in human PC cell lines and generation of B7H6 KO PC cell lines. (A) Surface expression of B7H6 on human pancreatic cancer cell lines (PANC-1, CFPAC-1, Capan-1, PL45) was assessed with a Fortessa X20 flow cytometer. (B) Immunoblotting detected B7H6 protein expression in human pancreatic cancer cell lines, with K562 as a positive control. GAPDH was used as a loading control. (C) sB7H6 secreted by pancreatic cancer cells into supernatants at 24 and 48 hours was analyzed by ELISA. Medium collected from K562 or RPMI-1640 served as a positive or negative control, respectively. Data from at least 3 independent experiments are shown as mean ± SEM. (D) Immunoblotting detected the protein expression of B7H6 after what was knocked out by CRISPR/Cas9 from PANC-1 and Capan-1 cells. beta -actin was the internal control (E) Quantification of B7H6 protein expression on PANC-1 and Capan-1 cells normalized to beta -actin. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35311080), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human B7-H6 by Western Blot B7H6 expression in human PC cell lines and generation of B7H6 KO PC cell lines. (A) Surface expression of B7H6 on human pancreatic cancer cell lines (PANC-1, CFPAC-1, Capan-1, PL45) was assessed with a Fortessa X20 flow cytometer. (B) Immunoblotting detected B7H6 protein expression in human pancreatic cancer cell lines, with K562 as a positive control. GAPDH was used as a loading control. (C) sB7H6 secreted by pancreatic cancer cells into supernatants at 24 and 48 hours was analyzed by ELISA. Medium collected from K562 or RPMI-1640 served as a positive or negative control, respectively. Data from at least 3 independent experiments are shown as mean ± SEM. (D) Immunoblotting detected the protein expression of B7H6 after what was knocked out by CRISPR/Cas9 from PANC-1 and Capan-1 cells. beta -actin was the internal control (E) Quantification of B7H6 protein expression on PANC-1 and Capan-1 cells normalized to beta -actin. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35311080), licensed under a CC-BY license. Not internally tested by R&D Systems.